

Medtronic deep brain stimulation (DBS)


There's a reason Medtronic has the most implanted deep brain stimulation (DBS) systems in the world.¹

As the originator and world leader in DBS for over 30 years, we have helped over 180,000¹ people with our innovative and life-changing therapy.

Driven by our passion to deliver the best outcomes, we are continuously advancing to develop breakthrough innovation that adapts to the evolving needs of patients.


Medtronic is your dedicated and proven partner to support you through your DBS journey.

Medtronic DBS therapy is approved for five indications: Parkinson's disease, essential tremor, dystonia*, obsessive-compulsive disorder* (OCD), and epilepsy. Indications vary by product. Refer to product labeling for details. *Humanitarian device: The effectiveness of these devices for the treatment of dystonia and obsessive-compulsive disorder has not been demonstrated.



Percept[™] **family** with BrainSense[™] technology[†]

Medtronic has engineered the most advanced DBS system that is adaptable to your individual needs. The Percept^{M} family is the only DBS system available with BrainSense^{M} technology to provide a more complete picture of your day-to-day brain activities so your clinician can adapt your stimulation and personalize your therapy.




[†]The sensing feature of the Percept™ PC system and Percept™ RC system is intended for use in patients receiving DBS where chronically recorded bioelectric data may provide useful, objective information regarding patient clinical status. The majority of patients with Parkinson's disease have an identifiable signal. Signal may not be present or measurable in patients treated for essential tremor, dystonia*, epilepsy, or obsessive-compulsive disorder*.

^{*}Humanitarian device: The effectiveness of these devices for the treatment of dystonia and obsessive-compulsive disorder has not been demonstrated. ‡Essential tremor indicated for unilateral (single) lead placement.

[§]Not approved for obsessive-compulsive disorder.

ΩSenSight[™] extensions are approximately 26.7% smaller in diameter (excluding the distal connector end) and have a 64% reduction in the force required to elongate when compared to Medtronic 37085 and 37086 extensions.



Designed to meet your needs today and tomorrow

Personalized therapy

Only the Medtronic DBS Percept[™] family utilizes BrainSense[™] technology to capture and record real-time brain signals related to your symptoms. This sensing capability allows your clinician to see your brain activities at the exact time you experienced symptoms (even when symptoms occur outside of an office visit). As a result, your stimulation can be personalized and adapted by your clinician to optimize therapy and minimize side effects.

Comfortable

The Percept[™] neurostimulators are designed to have a low profile under your skin for your comfort and for minimal visibility of the implanted device.

Unlike other DBS systems,² the Percept[™] neurostimulators are compatible with 3T and 1.5T MRI scans for when you need high-quality imaging. For your comfort, Medtronic DBS stimulation can also remain on while you're getting an MRI.†

Ready for future advancements

The Medtronic DBS Percept[™] family is designed to facilitate expanded capabilities with software updates. This means you won't need to replace your Percept™ neurostimulator to upgrade your device when software advancements become available.



Percept[™] PC neurostimulator



Recharge-free

Designed for

People who are looking for all the benefits of the Percept[™] family without the need to periodically recharge their neurostimulator.

Size

Features a thinner,† curved design.

Battery life

Experience a low maintenance battery with an expected 5 years of service life[‡] without ever having to recharge.

Charging

†Percept™ PC as compared to Boston Scientific Vercise Genus™ P16 (MP92328632-05 REV B) and Abbott Infinity™ 5/7 IPG (ARTEN600150429 B).

‡For median energy use in DBS for PD patients, with moderate (up to 2 months per year) BrainSense™ technology usage

With the PC option, the neurostimulator does not require recharging.

Percept[™] RC

neurostimulator

15 8

Medironic

Percept™ RC

B35300

Designed for

People who are looking for all the benefits of the Percept[™] family with a long-lasting battery, and don't mind periodically recharging their neurostimulator.

Size

Features the smallest and thinnest rechargeable neurostimulator available.§

Battery life

Count on at least 15 years of service life with consistent stimulation and fast recharge performance. Medtronic patented battery technology has less battery fade than other rechargeable devices for a more reliable, long-lasting battery. $^{\Omega}$

Charging

Experience rapid recharging from 10% to 90% full charge in less than 1 hour.^{††} The typical number of days before needing to recharge can be up to 9 to 12 days.^{‡‡} If charging daily, recharging can take as little as 15 minutes.^{§§}

Rechargeable

§Percept™ RC as compared to Boston Scientific Vercise Genus™ R16 (MP92328632-05 REV B) and Abbott Liberta RC™ IPG (ARTEN600308953 A). ΩBoston Scientific Vercise Genus™ R16 has a variable 5-15 years of service life, depending on the stimulation settings and conditions (MP92366224-01 Rev G). The amount of time Abbott Liberta RC™ DBS Implantable pulse generator will provide active stimulation varies based on the stimulation settings and daily usage time (ARTEN600308953 A).

††For implant depths of up to 2.0 cm under normal conditions.

‡‡50th percentile usage will typically have 12 days between required recharges and 80th percentile usage is expected to have 9 days between required recharges (100% to 0%) with sensing OFF.

§§With sensing ON at 80th percentile therapy settings for implant depth of 1 cm.

Ask for Medtronic DBS-the most advanced DBS system powered by BrainSense™ technology.

Visit medtronic.com/dbs to learn more.

References

- 1. Medtronic data on file.
- 2. Abbott and Boston Scientific DBS systems are 1.5T MR conditional and stimulation cannot remain on during a MRI scan. ImageReady[¬] MRI Guidelines for Boston Scientific Deep Brain Stimulation Systems (MP92438760-07 Rev A). Abbott MRI Support DBS Full Systems (accessed April 10, 2024).

Brief Statement: Medtronic DBS therapy for Parkinson's disease, tremor, dystonia, obsessive-compulsive disorder, and epilepsy

Patients should always discuss the potential risks and benefits with a physician.

Medtronic DBS Therapy for Parkinson's Disease: Deep brain stimulation (DBS) helps control the movement symptoms of Parkinson's disease, including tremor, slowed movement, and stiffness. You may be a candidate for this therapy if you have had levodopa-responsive Parkinson's for at least 4 years and at least 4 months of movement symptoms not well controlled by medications or medication side effect such as unintended movements (dyskinesia).

Medtronic DBS Therapy for Tremor: Deep brain stimulation (DBS) delivers electrical stimulation to an area in the brain to help treat essential tremor. Electrical stimulation is only delivered to one side of the body and is used to treat tremor in one arm of the body. You may be a candidate for this therapy if you have essential tremor not adequately controlled by medications and the tremor is disabling

Medtronic DBS Therapy for Dystonia: Deep brain stimulation (DBS) therapy for dystonia is indicated for unilateral or bilateral stimulation of the internal globus pallidus (GPi) or the subthalamic nucleus (STN) as an aid in the management of chronic, intractable (drug refractory) primary dystonia, including generalized and/ or segmental dystonia, hemidystonia, and cervical dystonia (torticollis) in patients seven years of age or above.

Medtronic Reclaim™ DBS Therapy for Obsessive-Compulsive Disorder*: The Medtronic Reclaim™ DBS therapy is indicated for bilateral stimulation of the anterior limb of the internal capsule, AIC, as an adjunct to medications and as an alternative to anterior capsulotomy for treatment of chronic, severe, treatmentresistant obsessive-compulsive disorder (OCD) in adult patients who have failed at least three selective serotonin reuptake inhibitors (SSRIs).

Medtronic DBS Therapy for Epilepsy: Deep brain stimulation (DBS) therapy for epilepsy is an adjunctive therapy (used along with medications) that deliver electrical stimulation to an area in your brain to reduce the frequency of seizures. You may be a candidate for this therapy if you are 18 years of age or older and diagnosed with epilepsy characterized by partial-onset seizures, with or without secondary generalization, that are not adequately controlled by three or more antiepileptic medications. The Medtronic DBS system for epilepsy has demonstrated safety and effectiveness for patients who average six or more seizures per month over the three most recent months prior to implant of the DBS system (with no more than 30 days between seizures). The Medtronic DBS system for epilepsy has not been evaluated in patients with less frequent seizures.

Warning for obsessive-compulsive disorder:

Electroconvulsive Therapy (ECT) - The safety of ECT in patients who have an implanted deep brain stimulation (DBS) system has not been established. Induced electrical currents may interfere with the intended stimulation or damage the neurostimulation system components resulting in loss of therapeutic effect, clinically significant undesirable stimulation effects, additional surgery for system explantation and replacement, or neurological injury.

Placing the DBS system requires brain surgery, which can have serious and sometimes fatal complications including bleeding inside the brain, stroke, seizures, and infection. Once implanted, infection may occur, parts may wear through your skin, and the lead and/or extension connector may move. Medtronic DBS therapy could stop suddenly because of mechanical or electrical problems. Any of these situations may require additional surgery or cause symptoms to return, worsen or become life-threatening as with status dystonicus, which requires immediate medical treatment. Medtronic DBS therapy may cause new or worsening neurological or psychiatric symptoms. For epilepsy: cessation, reduction, or initiation of stimulation may potentially lead to an increase in seizure frequency, severity, and new types of seizures. Symptoms may return with an intensity greater than was experienced prior to system implant, including the potential for status epilepticus. Memory impairment has been reported, although no direct cause-and-effect relationship has been established.

In patients receiving Medtronic DBS therapy for Parkinson's disease or essential tremor, new onset or worsening depression, suicidal thoughts, suicide attempts, and suicide have been reported. In patients receiving Medtronic DBS therapy for dystonia or epilepsy, depression, suicidal thoughts, and suicide have been reported although no direct cause-and-effect relationship has been established. In patients receiving Medtronic DBS therapy for obsessive-compulsive disorder, depression, suicidal thoughts, and suicide have been reported.

This therapy is not for everyone. Implantation of a DBS system is contraindicated (not allowed) for patients who will be exposed to diathermy (deep heat treatment) or transcranial magnetic stimulation. Magnetic Resonance Imaging (MRI) should only be performed as described in the product labeling. The DBS system may interact with other medical devices and other sources of electromagnetic interference which may result in serious patient injury or death, system damage or changes to the neurostimulator or to stimulation.

A prescription is required. Not everyone who receives DBS therapy will receive the same results.

For further information, please call Medtronic at 1-(800) 328-0810 and consult Medtronic's website at www.medtronic.com/dbs.

*Humanitarian Device: Authorized by Federal Law as an aid in the management of chronic, intractable (drug refractory) primary dystonia, including generalized and/ or segmental dystonia, hemidystonia, and cervical dystonia (torticollis), in patients seven years of age or above. The effectiveness of the devices for treating these conditions has not been demonstrated. Authorized by Federal law for use as an adjunct to medications and as alternative to anterior capsulotomy for treatment of chronic, severe, treatment-resistant obsessive-compulsive disorder (OCD) in adult patients who have failed at least three selective serotonin reuptake inhibitors (SSRIs). The effectiveness of the devices for this use has not been demonstrated.

Rev 02/22

Medtronic

710 Medtronic Parkway Minneapolis, MN 55432-5604

Tel: (763) 514-4000 Fax: (763) 514-4879

medtronic.com

©2024 Medtronic. Medtronic, Medtronic logo, and Engineering the extraordinary are trademarks of Medtronic. All other brands are trademarks of a Medtronic company.

04/2024 - UC202401183b EN - [WF#10036636]